UNSPSC 51293013: Amitriptyline pamoate

This classification denotes a tricyclic antidepressant with the molecular formula C23H16O6.2C20H23N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YX6VNM127F. Most nations, for tariff and trade purposes, schedule amitriptyline pamoate under HS 29214980 and SITC 51454. As of Q4 2014, AMITRIPTYLINE PAMOATE remains US FDA's Preferred Term for this commodity. Amitriptyline pamoate bears US NLM identifiers UMLS ID C0770882 and NCI Concept Code C96201.

SMILES: CN(C)CCC=C1C2CCCCC2CCC3C1CCCC3.CN(C)CCC=C1C2CCCCC2CCC3C1CCCC3.C1CCC2C(C1)CC(C(C2CC3C4CCCCC4CC(C3O)C(=O)O)O)C(=O)O.

UNSPSC 51293013 Amitriptyline pamoate (Commodity) covers pharmaceutical products, but the single recent state and local opportunity on file—Seminole County, Florida's IFB for Naloxone and Safe Drug Deactivation Systems—shows no alignment with the code's nominal scope. The opportunity, posted June 30, 2026 with a response deadline of July 26, 2023, solicits naloxone (an opioid antagonist used in overdose response) and drug deactivation equipment through competitive sealed bidding, not the tricyclic antidepressant amitriptyline pamoate the code nominally describes. This mismatch suggests either a coding error in the opportunity or that amitriptyline pamoate procurement under this code lacks current visibility in the state and local market.

The geographic and issuing-body data is insufficient to characterize meaningful activity. A single county health procurement in Florida does not establish a pattern of demand, state distribution, or repeat buyer behavior. State and local procurement under UNSPSC 51293013 shows little relevant recent activity aligned with amitriptyline pamoate procurement.